Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Preferred Stock Liabilities (2016 - 2025)

Historic Preferred Stock Liabilities for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Q3 2025 value amounting to $146.9 million.

  • Rhythm Pharmaceuticals' Preferred Stock Liabilities rose 380.62% to $146.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.9 million, marking a year-over-year increase of 380.62%. This contributed to the annual value of $142.8 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Preferred Stock Liabilities of $146.9 million as of Q3 2025, which was up 380.62% from $145.5 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Preferred Stock Liabilities high stood at $146.9 million for Q3 2025, and its period low was $140.2 million during Q2 2024.